Reports 2022 revenue $14.24M, consensus $14.18M. "Over the past year, Agios has made significant progress toward our vision of transforming the lives of patients with rare diseases as we build a hematology franchise focused on diseases that share a common underlying pathophysiology, limited treatment options and profound unmet need," said Brian Goff, chief executive officer at Agios. "In 2022, we received regulatory approvals in the U.S., EU and Great Britain for PYRUKYND as the first and only disease-modifying treatment for adults with pyruvate kinase deficiency. We achieved our ambitious enrollment targets for our pivotal trials in thalassemia and sickle cell disease. We strengthened our company leadership with the appointments of new management team and Board members with deep expertise in rare diseases and global commercial strategy. We are poised for significant near- and long-term growth and look forward to a productive 2023, anticipating the readout of our Phase 2 sickle cell disease study and the completion of enrollment in our Phase 3 thalassemia studies, driving toward two additional PYRUKYND indications by 2026."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGIO:
- Agios Reports Fourth Quarter and Full Year 2022 Financial Results
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Agios Pharmaceuticals initiated with an Overweight at Piper Sandler
- Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
- Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases